Evidence map›Paper›PMID 26729947›Full record

ReviewIndian journal of pharmacology

Investigation of comparative effectiveness research in Asia, Europe, and North America.

Isha Patel, Rachel Rarus, Xi Tan, E K Lee, Jason Guy, Akram Ahmad, Jongwha Chang

Open access · greenAbstract readComparative StudyReview
In one paragraph

Review in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Isha PatelDepartment of Biopharmaceutical Sciences, Shenandoah University, Winchester, VA, USA.
Rachel RarusThe University of Toledo Medical Center, Toledo, OH, USA.
Xi TanDepartment of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, WV, USA.
E K LeeDepartment of Pharmaceutical Policy and Outcomes Research, Sungkyunkwan University, Seoul, South Korea.
Jason GuyDepartment of Biopharmaceutical Sciences, Shenandoah University, Winchester, VA, USA.
Akram AhmadDepartment of Clinical Pharmacy, UCSI University, Kuala Lumpur, Malaysia.
Jongwha ChangDepartment of Pharmaceutical, Social and Administrative Sciences, Samford University, Birmingham, AL, USA.
Shenandoah University · USSamford University · USSungkyunkwan University · KRUCSI University · MYUniversity of Toledo Medical Center · USWest Virginia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comparative effectiveness research (CER) is an important branch of pharmacoeconomics that systematically studies and evaluates the cost-effectiveness of medical interventions. CER plays instrumental roles in guiding government public health policy programs and insurance. Countries throughout the world use different methods of CER to help make medical decisions based on providing optimal therapy at a reduced cost. Expenses to the healthcare system continue to rise, and CER is one-way in which expenses could be curbed in the future by applying cost-effectiveness evidence to clinical decisions. China, India, South Korea, and the United Kingdom are of essential focus because these country's economies and health care expenses continue to expand. The structures and use of CER are diverse throughout these countries, and each is of prime importance. By conducting this thorough comparison of CER in different nations, strategies and organizational setups from different countries can be applied to help guide public health and medical decision-making in order to continue to expand the establishment and role of CER programs. The patient-centered medical home has been created to help reduce costs in the primary care sector and to help improve the effectiveness of therapy. Barriers to CER are also important as many stakeholders need to be able to work together to provide the best CER evidence. The advancement of CER in multiple countries throughout the world provides a possible way of reducing costs to the healthcare system in an age of expanding expenses.

Indexed as

Decision Making, Computer-AssistedEvidence-Based MedicineHealth Care CostsPatient-Centered CareAsiaComparative Effectiveness ResearchCost SavingsDrug CostsDrug IndustryDrug Therapy, Computer-AssistedEconomics, PharmaceuticalEuropeHumansNorth AmericaComparative effectiveness researchhealth care costspharmacoeconomics

Identifiers

PMID26729947
PMCPMC4689009
OpenAlexW2175518555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.